Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
The clinical impact of coronavirus infection in patients with hematologic malignancies and hematopoietic stem cell transplant recipients

Morgan Hakki, Rogan M. Rattray, Richard D. Press

1. Background

The clinical significance of respiratory viruses such as influenza, respiratory syncytial virus (RSV), parainfluenza viruses (PIVs), human metapneumovirus (hMPV), rhinovirus (RhV), and adenovirus (AdV) in patients with hematologic malignancies or recipients of autologous or allogeneic hematopoietic stem cell transplant (HSCT) is well described [1–8]. Far less data have been published that specifically address the impact of coronavirus (CoV) infection in these patients [9]. Lower respiratory tract disease (LRTD) due to CoV has been described on a case-report level [10–14], but a retrospective analysis of 46 bronchoalveolar lavage (BAL) samples obtained from HSCT recipients with any acute pulmonary process did not identify CoV in any sample [3]. Later, a prospective surveillance study in allogeneic HSCT recipients performed at a single center over the course of one year found a relatively high cumulative incidence of CoV infection (11%) in the first 100 days following allogeneic HSCT, but only one case in which CoV was detected in a lower respiratory tract sample [15]. Other series studying the impact of respiratory viral infections have not specifically or directly assessed the clinical impact of CoV in patients with hematologic malignancies and HSCT recipients [16–22].

2. Objectives

With an apparently high frequency of infection but relative paucity of information pertaining to the impact of CoV in patients...
3. Study design

3.1. Clinical specimen and data collection

All nasopharyngeal (NP) and BAL samples submitted from outpatient clinics and inpatient wards for respiratory virus testing between June 01, 2010 and July 01, 2013 at Oregon Health and Science University (OHSU) were included in this study. Demographic and clinical information pertaining to each patient testing positive for CoV or other respiratory viruses assayed as part of a multiplex PCR panel (described below), were obtained by medical chart review.

A patient was considered to have a hematologic malignancy if they were diagnosed with, and were receiving treatment for, any type of leukemia, lymphoma, multiple myeloma, aplastic anemia, mastocytosis, myelodysplastic syndrome, or amyloidosis. All patients who underwent allogeneic or autologous HSCT, or cord blood transplant (CBT), were included and classified as such regardless of the underlying disease necessitating transplant.

3.2. Respiratory virus testing

Testing was performed using a multiplex respiratory virus PCR panel assay (xTAG RVP; Luminex) [23] per manufacturer’s instructions. Since this assay does not distinguish between RhV and enterovirus (EnV), these results are grouped together in this analysis. The CoV PCR reagents that are included in the RVP testing kit were further validated for clinical testing (under College of American Pathologists (CAP)- and Clinical Laboratory Improvement Amendments (CLIA)- regulatory conditions) by the OHSU molecular diagnostics lab.

3.3. Definitions

A unique episode of infection was counted at the initial identification of a respiratory virus in an NP or BAL sample. When the same respiratory virus was identified in multiple consecutive samples from the same patient without interim negative test results, this was considered representative of prolonged shedding, and was therefore counted as a single unique episode of infection.

Mortality was attributed to respiratory virus infection if death was due to respiratory failure without identification of a cause other than a respiratory virus [19].

Respiratory virus inpatient-acquired infection was defined as onset of new symptoms, 4 days or more after admission to an inpatient ward.

Criteria for possible and proven LRTD were identification of a respiratory virus in an NP sample (possible LRTD) or BAL sample (proven LRTD), along with new pulmonary infiltrates on thoracic imaging [24].

3.4. Statistical analysis

Comparison of categorical variables between viral groups was performed using two-tailed Fisher’s exact test.

### Table 1

| Virus | Specimens positive | Unique episodes of infection |
|-------|--------------------|-----------------------------|
|       | Total (%) | NP | BAL | All patients (%) | HM + HSCT (%) |
| RhV/EnV | 342 (54.2) | 305 | 37 | 225 (48.8) | 148 (43.6) |
| PIV 3 | 58 (9.2) | 52 | 6 | 34 (7.4) | 29 (8.6) |
| CoV | 43 (6.8) | 40 | 3 | 38 (8.2) | 33 (9.7) |
| hMPV | 42 (6.6) | 38 | 4 | 38 (8.2) | 25 (7.4) |
| RSV A | 35 (5.5) | 33 | 2 | 29 (6.3) | 27 (8.0) |
| RSV B | 35 (5.5) | 32 | 3 | 30 (6.5) | 26 (7.7) |
| Influenza A | 26 (4.1) | 23 | 3 | 22 (4.8) | 18 (5.3) |
| Influenza B | 14 (2.2) | 12 | 2 | 12 (2.6) | 12 (3.5) |
| PIV 4 | 11 (1.7) | 11 | 0 | 11 (2.4) | 9 (2.6) |
| AdV | 11 (1.7) | 9 | 2 | 8 (1.7) | 2 (0.6) |
| PIV 2 | 10 (1.6) | 8 | 2 | 10 (2.2) | 8 (2.4) |
| PIV 1 | 4 (0.6) | 4 | 0 | 4 (0.9) | 2 (0.6) |

* a Percentage of 631 positive specimens.
* b Percentage of 461 unique episodes of infection in all patients who had RVPs submitted.
* c Hematologic malignancy.
* d Percentage of 339 unique episodes of infection in HM and HSCT patients.

### Results

4.1. CoV identification in patients with hematologic malignancies and HSCT recipients

A total of 1661 NP and BAL samples obtained from the general hospital inpatient and outpatient populations - inclusive of, but not limited, to HSCT recipients and hematologic malignancy patients - were analyzed. Of these, 631 samples (38%) submitted during 461 unique episodes of infection tested positive for a respiratory virus (Table 1). CoV was the third most-common virus identified after RhV/EnV and PIV3, accounting for 43 (6.8%) positive samples. Three BAL specimens were positive for CoV (see below), representing 7% of all CoV-positive samples.

Of the 461 unique episodes of infection, 339 (73.5%) were in the hematologic malignancy and HSCT patient populations (Table 1). CoV was identified in 38 (8.2%) episodes among all patients, and 33 (9.7%) of episodes among hematologic malignancy and HSCT patients. 19 (57.5%) of the 33 episodes of CoV infection in the HSCT and hematologic malignancy population were diagnosed during the winter months of December–March (Fig. 1). The 38 samples from the 33 hematologic malignancy and HSCT patients tested positive for CoV, with the majority (76.3%) being Group I subtypes (NL63 (n = 15) and 229E (n = 14)), as compared...
to Group II subtypes (OC43 (n = 5) and HKU1 (n = 4)). 30 of the 38 (78.9%) CoV positive samples were positive only for CoV, and the other 8 samples were co-infected with RhV [4], RSV A [2], hMPV [1], and both RSV A and AdV [1].

4.2. Clinical impact of CoV infection in patients with hematologic malignancies and HSCT recipients

In order to better define the role of CoV in respiratory tract syndromes among patients with hematologic malignancies and HSCT recipients, we limited our clinical analysis to patients infected only with CoV, excluding those co-infected with other respiratory viruses (Table 2). 29 patients were infected only with CoV, and of those 28 (96.5%) had an underlying hematologic malignancy (n = 8) or had undergone allogeneic (n = 15) or autologous (n = 5) HSCT. The clinical characteristics of CoV infection in these 28 patients were examined and compared to episodes of mono-infection with other respiratory viruses (PIV1-4, hMPV, RSV, and RhV/EnV) in the same patient population. The median age of those infected with CoV was similar to the other respiratory viruses analyzed. Surprisingly, CoV was identified significantly more often in females (64%) than males compared to hMPV, PIV1-4, and RhV/EnV, with a trend toward the same finding for RSV.

Five episodes of CoV infection (17.8%) were hospital-acquired. Four of these cases, all subtype NL63, occurred on the same inpatient HSCT/oncology ward within a 60 day period between January 27 and March 24, 2012. While indicative of an epidemiological link, we were unable to conclusively prove this. According to surveillance performed as part of OHSU’s Infection Control program, during this time period, only two other cases of nosocomial acquisition of a respiratory virus occurred on this ward – one RhV/EnV and one influenza A (personal communication, Dr. Lynne Strasfeld).

Of cases acquired as an outpatient, 7 (30.4%) required admission to the hospital, typically for evaluation of fevers or new pulmonary infiltrates. The requirement for hospitalization during CoV infection was not significantly different from those during infection with other respiratory viruses.

Similar to most other respiratory viruses, the majority of patients (85.7%) in whom CoV was detected had URI symptoms (rhinorrhea, congestion, or sore throat). However, evidence of LRTD patients (85.7%) in whom CoV was detected had URI symptoms in infiltrates. The requirement for hospitalization during CoV infection due to detection in asymptomatic shedders [15]. It is also important to note that the true rate of influenza A and B infection is under-represented in our results since the initial test of choice for these pathogens at our institution is an influenza-specific PCR assay, not the respiratory virus panel used in this study. Accounting for this would reduce the relative frequency of CoV as well as that of all other non-influenza respiratory viruses.

We found that the hematologic malignancy and HSCT populations accounted for the majority of patients testing positive for CoV and the other respiratory viruses. This finding almost certainly reflects testing bias in that these patients are more likely to be tested for respiratory viruses when symptomatic given the importance placed on these pathogens [9]. Interestingly, we also found a female-predominant gender distribution among those infected with CoV, which to the best of our knowledge, has not been reported before [15–17,25,26]. While the frequency of respiratory illnesses in the general population has been described to be higher among females, perhaps due to increased exposure [27], if this was responsible for the higher burden of CoV infection among women compared to men, then a similar pattern might be expected for the other respiratory viruses as well. This finding requires confirmation by additional studies.

The majority (76.3%) of CoV identified in the hematologic malignancy and HSCT patients in this study belongs to Group I. Similarly, Group I CoVs have been associated with infection in the immunocompromised host more than Group II CoVs in several series and case reports [12,13,15,26,28]. In contrast, studies involving general or pediatric patient populations have reported a majority of CoV belonging to Group II [16,17,25,26,29–32]. Group I and II CoVs differ in the mechanism of virus entry into the host cell and the degree of genetic variability, but whether these differences affect pathogenicity is not known [33]. Indeed, reports associating CoV subtypes with disease manifestations are conflicting [17,26,31]. Further studies into the relative incidence of CoV subtypes among various patient populations are necessary and may provide insight into fundamental biological differences between Group I and II subtypes.

Similar to previous reports [3,15], the rate of CoV-proven LRTD was low but was not significantly different from other respiratory viruses. However, these results must be interpreted with caution since bronchoscopy, which we used as a criteria for defining “proven LRTD”, is no longer done in many cases when a respiratory virus is identified in an upper airway sample at this institution or others [24]. Analyzing “possible LRTD” instead, CoV was indeed associated with significantly less disease compared to all other respiratory viruses analyzed except RhV/EnV, with the rate of possible LRTD due to the other respiratory viruses in this report being
Table 2
Clinical characteristics of CoV monoinfection compared to other respiratory viruses in hematologic malignancy and HSCT patients.

| Characteristic                                      | Respiratory virus          |
|-----------------------------------------------------|----------------------------|
|                                                     | CoV (n=28) | hMPV (n=23) | PIV 1–4 (n=45) | RSV (n=42) | RhV/EnV (n=137) |
| Median age in years (range)                         | 55 (2–73)   | 57 (18–68)  | 55 (2–72)      | 50 (2–78)  | 52 (1–80)       |
| Gender (%)                                          |             |             |                |            |                |
| Male                                                | 10 (35.7)   | 17 (73.9)*  | 29 (64.4)*     | 25 (59.5)  | 79 (57.7)*      |
| Female                                              | 18 (64.3)   | 6 (26.1)    | 16 (35.6)      | 17 (40.5)  | 58 (42.3)       |
| Underlying condition                                |             |             |                |            |                |
| Allogeneic HSCT                                     | 15          | 14          | 29             | 26         | 60              |
| Autologous HSCT                                     | 5           | 2           | 3              | 6          | 15              |
| CBT                                                 | 0           | 0           | 1              | 2          | 4               |
| Hematologic malignancy                              | 8           | 7           | 12             | 8          | 58              |
| Nosocomial acquisition (%)                          | Yes         | 5 (17.8)    | 2 (8.7)        | 5 (11.1)   | 4 (9.5)         | 22 (16.1) |
| Required admission if outpatient (%)                | Yes         | 7 (30.4)    | 7 (33.3)       | 19 (47.5)  | 16 (42)         | 35 (30.4) |
| Manifestations of infection (%)                     | Fever       | 11 (39.3)   | 10 (43.4)      | 21 (46.7)  | 21 (50)         | 42 (30.6) |
| URI symptoms                                        | 24 (85.7)   | 17 (73.9)   | 29 (64.4)      | 34 (80.6)  | 82 (59.9)*      |
| Cough                                               | 13 (46.4)   | 21 (91.3)***| 41 (91.1)**    | 34 (80.6)  | 93 (67.9)       |
| Hypospasia                                          | 2 (7.1)     | 5 (21.7)    | 12 (26.7)      | 9 (21.4)   | 20 (14.6)       |
| Abnormal chest imaginga                             | 5 (20)      | 12 (52.2)   | 27 (60)        | 24 (64.7)*| 38 (24.7)       |
| Possible LRTD (%)                                   | 3 (10.7)    | 10 (43.5)***| 22 (48.9)**    | 19 (45.2)*| 29 (21.2)       |
| Proven LRTD (%)                                     | 2 (7.1)     | 2 (8.7)     | 5 (11.1)       | 5 (11.9)   | 9 (6.6)         |
| Infection-attributable mortality (%)               | 0           | 0           | 2 (4.4)        | 2 (4.8)    | 1 (0.7)         |

† P value ≤ 0.05.
二是 P value ≤ 0.005.
*** P value = 0.01.
* Not all patients had chest imaging performed.

a Generally consistent with the published literature [9,24]. However, not all patients had radiography performed at the time of diagnosis of respiratory viral infection, which may bias the results toward those more likely to have evidence of lower respiratory tract illness.

Interestingly, all cases of possible and proven CoV-associated LRTD occurred in HSCT recipients, whereas the cases of possible and proven LRTD during infection with the other respiratory viruses were divided more evenly among HSCT recipients and hematologic malignancy patients. Additionally, all cases occurred in the setting of acute or chronic GVHD. Taken together, these findings suggest that CoV may be inherently less virulent compared to other respiratory viruses, and therefore, requires augmented immune suppression after HSCT in order to progress to LRTD. The low number of CoV-associated LRTD in this study precludes meaningful risk factor assessment but additional studies may make this more feasible.

Aside from LRTD, CoV infection was associated with other clinically-relevant consequences. Namely, 30% of outpatients were admitted to the hospital based on manifestations of CoV infection, and hospital acquisition occurred in 5 cases, with a cluster of 4 nosocomially-acquired cases occurring within a 2 month span. Additionally, 50% of CoV-infected patients received an empiric course of antibacterial therapy (data not shown). Notably, while CoV is detected as part of the respiratory virus panel used at our institution during the study period, the CoV results were not reported in the medical record since the assay was not approved by the Food and Drug Administration for this purpose. In theory, a “negative” respiratory virus panel result may lead to more frequent admission to the hospital for further medical evaluation, antibacterial use, or nosocomial transmission. However, we found the rates of these events during CoV infection to be similar to those during infection with other respiratory viruses (Table 2 and data not

Table 3
Cases of possible and proven CoV LRTD in HSCT recipients.

| HSCT (days)                   | Donor type | Age       | Gender | Subtype | GVHD | Steroid doseab | ALCd (cells/μL) | Co-pathogen |
|--------------------------------|------------|-----------|--------|---------|------|----------------|-----------------|-------------|
| Possible                       |            |           |        |         |      |                |                 |             |
| 1                              | Allogeneic | 45        | M      | 229E    | Yes  | 0.75           | 700             | No          |
| 2                              | Allogeneic | 55        | M      | 229E    | Yes  | None           | 700             | No          |
| 3                              | Allogeneic | 69        | F      | OC43    | Yes  | 0.5            | 100             | No          |
| Proven                         |            |           |        |         |      |                |                 |             |
| 1                              | Allogeneic | 41        | M      | 229E    | Yes  | Noneab         | 400             | No          |
| 2                              | Allogeneic | 51        | F      | OC43    | Yes  | 0.5            | 300             | AdV, RSV, MRSA |

a Indicates number of days between HSCT and CoV infection.
b At the time of CoV infection.
c Mg/kg/day.
d Absolute lymphocyte count.
ab Sirolimus, tacrolimus, and rituximab for steroid-refractory chronic GVHD.
Ac Methicillin-resistant Staphylococcus aureus.
shown), highlighting the overall impact of respiratory viral infections in these patients in terms of utilization of medical resources.

In conclusion, we found that CoV is detected frequently in patients with hematologic malignancies and HSCT recipients in whom suspicion for a respiratory viral infection exists, but is associated with less LRTD than other respiratory viruses except RhV/EnV.

The retrospective nature of this work mandates confirmation of our findings by additional, prospective studies.

Conflicts of interest

No conflicts of interest.

Competing interest

None declared.

Ethical approval

Approval from the Institutional Review Board of OHSU was obtained prior to beginning this study.

Acknowledgments

The authors wish to thank Dr. Lynne M. Strasfeld and Kevin Langstaff for providing data pertaining to nosocomially-acquired respiratory viral infections at OHSU.

References

[1] M.C. Debur, L.R. Vidal, E. Stroparo, M.B. Nogueira, S.M. Almeida, G.A. Takahashi, I. Rotta, L.A. Pereira, C.S. Silveira, C.M. Bonfim, S.M. Raboni, Human metapneumovirus infection in hematopoietic stem cell transplant recipients, Transpl. Infect. Dis. 12 (2010) 173–179.

[2] S. Ghosh, R. Champlin, R. Couch, J. Englund, I. Raad, S. Malik, M. Luna, E. Whimbey, Rhinovirus infections in myelosuppressed adult blood and marrow transplant recipients, Clin. Infect. Dis. 29 (1999) 528–532.

[3] M.G. Ison, F.G. Hayden, L. Kaiser, L. Corey, M. Boeckh, Rhinovirus infections in hematopoietic stem cell transplant recipients with pneumonia, Clin. Infect. Dis. 36 (2003) 1139–1144.

[4] M. Kamboj, M. Gerbin, C.K. Huang, C. Brennan, J. Stiles, S. Balashov, A. Saracini, A. Cordonnier, Respiratory virus infections after stem cell transplantation: a prospective study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation, Bone Marrow Transpl. 28 (2001) 479–484.

[5] R. Martin, R.P. Porras, N. Rabel, J.V. Williams, E. Ramila, N. Margail, R.L. Lloaga, J.E. Crowe Jr., P. Coll, J. Sierra, Prospective study of the incidence, clinical features, and outcome of upper and lower respiratory tract infections by respiratory viruses in adult recipients of hematopoietic stem cell transplants for hematologic malignancies, Biol. Blood Marrow Transpl. 11 (2005) 791–796.

[6] M. Mukulska, V. Del Bono, N. Gandolfo, S. Dini, A. Dominietto, C. Di Grazia, S. Bregante, R. Varaldo, A. Orsi, F. Ansaldi, A. Bacigalupo, V. Viscoli, Epidemiology of viral respiratory tract infections in an outpatient haematology facility, Ann. Hematol. 91 (2012) 646–707.

[7] A. Wolfrobin, R. Porcher, J. Legoff, R.P. de Latour, A. Xhaard, F.S. de Fontbrune, P. Ribaud, A. Bergeron, G. Socie, M. Robin, Viral respiratory infections diagnosed by multiple PCR after allogeneic hematopoietic stem cell transplantation: long-term incidence and outcome, Biol. Blood Marrow Transpl. 20 (August (8)) (2014) 1238–1241.

[8] N. Krunic, T.D. Yager, D. Himsworth, F. Merante, S. Yaghoubian, R. Janeczko, tXAG RVP assay: analytical and clinical performance, J. Clin. Virol. 40 (Suppl. 1) (2007) S39–S46.

[9] S. Seo, H. Xie, A.P. Campbell, J.M. Kuyper, W.M. Leisenring, J.A. Englund, M. Boeckh, Parainfluenza virus lower respiratory tract disease after hematopoietic cell transplantation: viral detection in the lung predicts outcome, Clin. Infect. Dis. 58 (2014) 1377–1368.

[10] J. Kuyper, E.T. Martin, J. Heugel, N. Wright, R. Morrow, J.A. Englund, Clinical disease in children described with newly described coronavirus subtypes, Pediatrics 119 (2007) e70–76.

[11] E.R. Gaunt, A. Hardie, E.C. Caas, P. Simmonds, K.E. Templeton, Epidemiology and clinical presentation of four human coronaviruses 229E, HKU1, NL63, and OC43 detected over 3 years using a novel multiplex real-time PCR method, J. Clin. Microbiol. 48 (2010) 2940–2947.

[12] A.S. Monto, Epidemiology of viral respiratory infections, Am. J. Med. 112 (Suppl. 6A) (2002) 45–125.

[13] D. Kumar, S. Husain, M.H. Chen, G. Moussa, D. Himsworth, O. Manuel, S. Studer, D. Pakstis, K. McCurry, K. Doucette, J. Pilewski, R. Janeczko, A. Humar, A prospective molecular surveillance study evaluating the clinical impact of community-acquired respiratory viruses in lung transplant recipients, Transplantation 89 (2010) 1028–1033.

[14] R.K. Dare, A.M. Fry, M. Chittaganpitch, P. Sawanpanyalert, S.J. Olsen, D.D. Erdman, Human coronavirus infections in rural Thailand: a comprehensive retrospective study using real-time reverse-transcription polymerase chain reaction assays, J. Infect. Dis. 196 (2007) 1321–1328.

[15] N. Krunic, T.D. Yager, D. Himsworth, F. Merante, S. Yaghoubian, R. Janeczko, tXAG RVP assay to identify coronavirus HKU1 in the lungs of a hematopoietic stem cell transplant recipient, Transpl. Infect. Dis. 1 (2007) S39–S46.

[16] P. Ljungman, K.N. Ward, B.N. Crooks, A. Parker, R. Martino, P.J. Shaw, L. Brinch, I.A. Hassan, R. Chopra, R. Swindell, K.J. Mutton, Respiratory viral infections after bone marrow/peripheral stem–cell transplantation: the Christie hospital experience, Bone Marrow Transpl. 32 (2003) 73–77.

[17] F. Pene, A. Merlat, A. Vahret, F. Rozenberg, A. Buzyn, F. Dreyfus, A. Cariou, F. Freymuth, F. Lebon, Coronavirus 229E–related pneumonia in immunocompromised patients, Clin. Infect. Dis. 37 (2003) 929–932.

[18] C. Uhlenhaert, J.I. Cohen, S. Pavletic, G. Illei, J.C. Ce a-Banacloche, M. Abu-Asab, T. Krogmann, L. Gubareva, S. McMahan, P.R. Krause, Use of a novel virus detection assay to identify coronavirus HKU1 in the lungs of a hematopoietic stem cell transplant recipient with fatal pneumonia, Transpl. Infect. Dis. 14 (2012) 79–85.

[19] F. Milano, A.P. Campbell, K.A. Guthrie, J. Kuyper, J.A. Englund, L. Corey, M. Boeckh, Human rhinovirus and coronavirus detection among allogeneic hematopoietic stem cell transplantation recipients, Blood 115 (2010) 2088–2094.

[20] J. Garhio, S. Crespo, J.D. Aubert, T. Rochat, B. Ninet, C. Deffernez, W. Wunderli, J.C. Pache, P.M. Soccal, L. Kaiser, A prospective hospital-based study of the clinical impact of non-severe acute respiratory syndrome (Non-SARS)–related human coronavirus infection, Clin. Infect. Dis. 43 (2006) 1009–1015.

[21] G. Gerna, G. Campani, A. Mennini, F. Rovida, E. Pecorale, A. Saracini, A. Cordonnier, Genetic variability of human coronavirus OC43-, 229E-, and NL63-like strains and their association with lower respiratory tract infections of hospitalized infants and immunocompromised patients, J. Med. Virol. 78 (2006) 938–949.

[22] L.Oosterhof, C.B. Christensen, H. Sengelov, Fatal lower respiratory tract disease with human corona virus NL63 in an adult hematopoietic cell transplant recipient, Bone Marrow Transpl. 45 (2010) 1115–1116.